

Docket: 51876AUSM1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor:	CROZE, et al.	RECEIVED CENTRAL EXAMINER DEC 22 2004
Appln. No.:	09/912,252	
Filing Date:	July 25, 2001	
Title:	Use of the Interferon Receptor 2c Polypeptide Chain to Enhance the Anti-Growth Effects of Type I Interferons	
Examiner:	Q. Nguyen	
Group Art Unit:	1636	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mailstop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 CFR §1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references cited on the attached form PTO-1449 (a copy of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. §1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.


We hereby certify that the items set forth on the attached form PTO-1449 were not first cited in a communication from a foreign patent office in a counterpart foreign application and, to our knowledge, after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Supplemental Information Disclosure Statement.

This IDS is being filed after the mailing of a final action on the merits, therefore, pursuant to §1.97(d)(1)(2), the Commissioner is hereby authorized to charge \$180.00 to our deposit account #02-2117 and for any fees necessary to facilitate the filing of this application (a duplicate copy of this sheet is enclosed.). This is, however, not authorization to pay the issue fee. Please acknowledge receipt of this Supplemental IDS and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

BERLEX INC.

Customer Number 27586


Wendy L. Washtien, Reg. No. 36,301Date: Dec 22, 2004

Corporate Patents
2600 Hilltop Drive
Richmond, California 94806
(510) 262-5000

DEC 22 2004

Sheet 1 of 1

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 51876AUSM1		APPLICATION NO. 09/912,252	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS CROZE et al.			
				FILING DATE July 25, 2001		GROUP ART UNIT 1636	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	1.	Platanias, et al., "Identification of a Domain in the β Subunit of the Type I Interferon (IFN) Receptor That Exhibits a Negative Regulatory Effect in the Growth Inhibitory Action of Type I IFNs", <i>The Journal of Biological Chemistry</i> , Vol 273, No. 10, Issue of March 6, pp. 5577-5581, 1998.					
	2.	Qin et al., "Interferon- β Gene Therapy Inhibits Tumor Formation and Causes Regression of Established Tumors in Immune-Deficient Mice", <i>Proc. Natl. Acad. Sci. USA</i> , Vol 95, pp. 14411-14416, November 1998, <i>Medical Sciences</i>					
	3.	Wagner et al., "Interferon Receptor Expression Regulates the Antiproliferative Effects of Interferons on Cancer Cells and Solid Tumors", <i>Int. J. Cancer</i> : 111,32-42 (2004).					
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							

Forms/Pat/P7-27 [01/31/01]